The impact of age and high-risk human papillomavirus (hrHPV) status on the prevalence of high-grade cervical intraepithelial neoplasia (CIN2+) in women with persistent hrHPV-positive, cytology-negative screening samples: a prospective cohort study
- PMID: 32279427
- DOI: 10.1111/1471-0528.16250
The impact of age and high-risk human papillomavirus (hrHPV) status on the prevalence of high-grade cervical intraepithelial neoplasia (CIN2+) in women with persistent hrHPV-positive, cytology-negative screening samples: a prospective cohort study
Abstract
Objective: To establish the prevalence of high-grade cervical intraepithelial neoplasia (CIN2+) in women referred to colposcopy with persistent high-risk human papillomavirus (hrHPV) cytology-negative screening sample according to hrHPV genotype, age at referral and colposcopic performance.
Design: Prospective cohort study.
Setting: Single colposcopy clinic linked to a population-based screening programme.
Population: Women referred with persistent hrHPV cytology-negative routine screening samples.
Methods: Prospective study with descriptive statistics from a single colposcopy unit between June 2014 and July 2019.
Main outcome measures: Prevalence of hrHPV genotypes and CIN2+, positive predictive value for colposcopic impression, and inadequate colposcopic examinations.
Results: A total of 3107 women were referred. Prevalence of CIN2+ was highest for persistent HPV16 infections (10.7%) compared with HPV18 (3.6%) or HPVO (4.7%). Prevalence of CIN2+ declined with age (25-34 years 14.2% to 55-64 years 1.1%) whereas the percentage of women with an inadequate colposcopic examination increased (25-34 years 0.9% to 55-64 years 29.5%). High-grade colposcopic impression fell over time during the study from 16.1 to 5.1%. The positive predictive value for colposcopic impression of CIN2+ was affected by hrHPV genotype (57.3% for HPV16 versus 32.1% for nonHPV16). The adjunctive use of electrical impedance spectroscopy detected an extra 42 cases of CIN2+, which was irrespective of hrHPV genotype.
Conclusions: Primary hrHPV cervical screening increases detection of CIN2+; however, low specificity results in more women being referred to colposcopy with a low prevalence of CIN2+. Colposcopy performs poorly in some groups, particularly with HPVO infections and women over 50 years of age. An appropriate threshold for referral to colposcopy in primary hrHPV screening has not been established.
Tweetable abstract: Low prevalence of CIN2+ in HPV-positive negative cytology samples. HPV genotype, age and prevalence of CIN2+ affect colposcopic performance.
Keywords: Cervical neoplasia; colposcopy; human papillomavirus; screening.
© 2020 Royal College of Obstetricians and Gynaecologists.
Comment in
-
Better triage tests needed for HPV-positive women.BJOG. 2020 Sep;127(10):1268. doi: 10.1111/1471-0528.16320. Epub 2020 May 28. BJOG. 2020. PMID: 32416630 No abstract available.
Similar articles
-
The clinical effectiveness and cost-effectiveness of primary human papillomavirus cervical screening in England: extended follow-up of the ARTISTIC randomised trial cohort through three screening rounds.Health Technol Assess. 2014 Apr;18(23):1-196. doi: 10.3310/hta18230. Health Technol Assess. 2014. PMID: 24762804 Free PMC article. Clinical Trial.
-
Influence of high risk HPV genotype on colposcopic performance: A large prospective study demonstrates improved detection of disease with ZedScan I, particularly in non-HPV 16 patients.Eur J Obstet Gynecol Reprod Biol. 2017 Apr;211:194-198. doi: 10.1016/j.ejogrb.2017.02.020. Epub 2017 Feb 20. Eur J Obstet Gynecol Reprod Biol. 2017. PMID: 28292693
-
The impact of human papillomavirus genotype on colposcopic appearance: a cross-sectional analysis.BJOG. 2014 Aug;121(9):1117-26. doi: 10.1111/1471-0528.12668. Epub 2014 Feb 4. BJOG. 2014. PMID: 24494663
-
Risk of Cervical Intraepithelial Neoplasia 2 or Worse by Cytology, Human Papillomavirus 16/18, and Colposcopy Impression: A Systematic Review and Meta-analysis.Obstet Gynecol. 2018 Sep;132(3):725-735. doi: 10.1097/AOG.0000000000002812. Obstet Gynecol. 2018. PMID: 30095780 Free PMC article.
-
Risk of Cervical Dysplasia After Colposcopy Care and Risk-Informed Return to Population-Based Screening: A Systematic Review.J Obstet Gynaecol Can. 2020 May;42(5):607-624. doi: 10.1016/j.jogc.2019.05.017. Epub 2019 Nov 1. J Obstet Gynaecol Can. 2020. PMID: 31679914
Cited by
-
Added value of electrical impedance spectroscopy in adjunction of colposcopy: a prospective cohort study.BMJ Open. 2023 Oct 29;13(10):e074921. doi: 10.1136/bmjopen-2023-074921. BMJ Open. 2023. PMID: 37899156 Free PMC article.
-
Risk Profile of High-grade Cervical Lesions and Cervical Cancer Considering the Combination of Cytology, HPV Genotype, and Age among Women Undergoing Colposcopy.Rev Bras Ginecol Obstet. 2023 Nov;45(11):e689-e698. doi: 10.1055/s-0043-1772483. Epub 2023 Nov 29. Rev Bras Ginecol Obstet. 2023. PMID: 38029771 Free PMC article.
-
Improving diagnostic of cervical dysplasia among postmenopausal women aged ≥50 years using local vaginal oestrogen treatment prior to colposcopy: study protocol for a multicentre randomised controlled trial (the IDEAL study).BMJ Open. 2024 Jun 23;14(6):e082833. doi: 10.1136/bmjopen-2023-082833. BMJ Open. 2024. PMID: 38910002 Free PMC article.
-
Genotype-specific Distribution and Change of High-risk Human Papillomavirus Infection and the Association with Cervical Progression Risk in Women with Normal Pathology and Abnormal Cytology in a Population-based Cohort Study in China.J Cancer. 2021 May 19;12(14):4379-4388. doi: 10.7150/jca.57993. eCollection 2021. J Cancer. 2021. PMID: 34093838 Free PMC article.
-
Which is the best management for women with normal cervical cytologic findings despite positivity for non-16/18 high risk human papillomaviruses?Front Public Health. 2022 Nov 9;10:950610. doi: 10.3389/fpubh.2022.950610. eCollection 2022. Front Public Health. 2022. PMID: 36438260 Free PMC article. Review.
References
-
- RoncoG, DillnerJ, ElfströmKM, TunesiS, SnijdersPJ, ArbynM, et al. Efficacy of HPV-based screening for prevention of invasive cervical cancer: follow-up of four European randomised controlled trials. Lancet2014;383:524-32.
-
- KitchenerHC, AlmonteM, ThomsonC, WheelerP, SargentA, StoykovaB, et al. HPV testing in combination with liquid-based cytology in primary cervical screening (ARTISTIC): a randomised controlled trial. Lancet Oncol2009;10:672-82.
-
- ReboljM, RimmerJ, DentonK, TidyJ, MathewsC, EllisK, et al. Primary cervical screening with high risk human papillomavirus testing: observational study. BMJ2019;364:l24.
-
- KellyRS, PatnickJ, KitchenerHC, MossSM, NHSCSP HPV Special Interest Group. HPV testing as a triage for borderline or mild dyskaryosis on cervical cytology: results from the Sentinel Sites study. Br J Cancer2011;105:983-8.
-
- Cervical Screening Programme, England - 2018-19 [https://digital.nhs.uk/data-and-information/publications/statistical/cer.... Accessed 2 January 2020.